News
Sarepta Therapeutics, Duchenne and Gene
Digest more
Muscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, causing ...
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...
Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
Participants with Duchenne muscular dystrophy (DMD) who received RGX-202 demonstrated functional improvement and better ...
The drug, Givinostat, has been approved as safe for use but Belfast Health Trust, NI's specialist centre for the condition, ...
Parents of children with an incurable muscle-wasting condition have called on the Minister for Health to accelerate the ...
Hosted on MSN13d
Cardiac Complications of Duchenne Muscular DystrophyCardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies ...
4d
U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...
The parents of a nine-year-old boy battling a devastating muscle-wasting condition say new research could offer them more ...
Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback